Raymond James upgraded Nkarta to Strong Buy from Outperform with an unchanged price target of $16 following the Q2 report. The shares are currently trading below the company’s cash position of $5.80 and a “strong cash runway” into late 2027 gets Nkarta through “numerous de-risking catalysts,” the analyst tells investors in a research note. The firm believes investors are underappreciating NKX019 that support its “best in class potential.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTX:
- Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
- Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
- Nkarta’s (NKTX) Making Promising Progress in Its Clinical-Stage Journey
- Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus
- Nkarta initiates trial of NKX019 in lupus erythematosus